The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesPeptide ELISA: Antibody detection limit dilution 1:64,000.
WB: Use at a concentration of 0.1 - 0.3 µg/ml. Predicted molecular weight: 88 kDa.
Experiments gave bands at approx 80-90kDa and strong ladder from 26 to 38kDa in Human Prostate lysates after 0.3ug/ml antibody staining. The observation of multiple bands and the 38 kDa band correspond to earlier findings in literature (Powell et al, Am J Respir Cell Mol Biol. 2004 Jul;31(1):13-21; PMID: 14742294).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Tissue specificityExpressed in all tissues, except liver, with high expression in placenta, lung, spleen and veins.
Involvement in diseaseGenetic variations in ADAM33 are associated with susceptibility to asthma (ASTHMA) [MIM:600807]. The most common chronic disease affecting children and young adults. It is a complex genetic disorder with a heterogeneous phenotype, largely attributed to the interactions among many genes and between these genes and the environment. It is characterized by recurrent attacks of paroxysmal dyspnea, with weezing due to spasmodic contraction of the bronchi.
DomainThe conserved cysteine present in the cysteine-switch motif binds the catalytic zinc ion, thus inhibiting the enzyme. The dissociation of the cysteine from the zinc ion upon the activation-peptide release activates the enzyme.
Post-translational modificationsThe precursor is cleaved by a furin endopeptidase.